Cover Image
Market Research Report
Product code 
1064084

Antibody Discovery Services and Platforms Market (4th Edition): Distribution by Type of Service Offered (Antigen Designing, Hit Generation, Lead Selection, Lead Optimization, Lead Characterization), Antibody Discovery Method

Published: | Roots Analysis | 536 Pages | Delivery time: 1-2 business days

Price

Back to Top
Antibody Discovery Services and Platforms Market (4th Edition): Distribution by Type of Service Offered (Antigen Designing, Hit Generation, Lead Selection, Lead Optimization, Lead Characterization), Antibody Discovery Method
Published: March 9, 2022
Roots Analysis
Content info: 536 Pages
Delivery time: 1-2 business days
  • Description
  • Table of Contents
  • List of Tables

Title:
Antibody Discovery Services and Platforms Market (4th Edition):
Distribution by Type of Service Offered (Antigen Designing, Hit Generation, Lead Selection, Lead Optimization, Lead Characterization), Antibody Discovery Method (Library based, Hybridoma based, Single Cell based, Transgenic Animal based), Nature of Antibody Generated (Humanized, Human, Chimeric, Murine) and Key Geographies (North America, Europe, Asia-Pacific, Latin America, and Middle East and North Africa): Industry Trends and Global Forecasts, 2022-2035.

Example Insights:

Overview:

Since the approval of Orthoclone OKT3, a murine monoclonal antibody against T cell expressed CD3 (for the treatment of acute transplant rejection) in 1986, antibody therapeutics have evolved into a prominent class of therapeutics. These therapeutics have high target specificities and favorable safety profiles. Currently, close to 100 monoclonal antibodies have been approved while more than 500 molecules are being evaluated in clinical trials. Some of the recently approved monoclonal antibody therapies include (in reverse chronological order) Tivdak® (September 2021), Saphnelo® (August 2021), Rybrevant® (May 2021), Ebanga (December 2020) and MARGENZA® (December 2020). The growing popularity of antibody based therapeutics is also reflected from the extensive research being conducted on other novel antibody formats, such as bispecific antibodies, antibody drug conjugates (ADCs) and antibody fragments in the past few years.

It is worth highlighting that the process of antibody development, beginning from the discovery to the commercialization of a clinically validated product, takes around 10-15 years. Moreover, antibody discovery and clinical research are capital intensive processes, which, on an average, require investments of around USD 4-10 billion. Further, it is a well-known fact that only a small proportion of lead molecules that are shortlisted for further investigation during the discovery phase make it into the clinical phase, and an even lesser number of product candidates enter the market. In order to optimize on internal resource utilization and save costs, pharmaceutical companies are increasingly outsourcing various aspects of their discovery-stage operations to specialty contract research organizations (CROs). Apart from being considered a viable business strategy, engaging third party service providers offers both time and cost related benefits to the drug / therapy developers. Given the rising demand for antibody based therapeutics and growing preference for outsourcing, we are led to believe that the opportunity for contract service provides and technology developers is likely to increase at a steady rate in the foreseen future.

Scope of the Report:

The "Antibody Discovery Services and Platforms Market by Type of Service Offered (Antigen Designing, Hit Generation, Lead Selection, Lead Optimization, Lead Characterization), Antibody Discovery Method (Library based, Hybridoma based, Single Cell based, Transgenic Animal based), Nature of Antibody Generated (Monoclonal, Bispecific, Antibody-Drug Conjugates, Antibody Fragments) and Key Geographies (North America, Europe, Asia-Pacific, Latin America, and Middle East and North Africa): Industry Trends and Global Forecast (4th Edition), 2021-2035" report features an extensive study on the current market landscape, offering an informed opinion on the likely evolution in this industry over the next ten years. The study underlines an in-depth analysis of the antibody discovery technologies and services that assist in the development of antibody therapeutics. In addition to other elements, it includes:

  • An overview of the overall landscape of antibody discovery service providers along with the information on a number of parameters, such as year of establishment, company size, location of headquarters, type of service offered (antigen designing, hit generation, lead selection, and lead optimization and lead characterization), type of antibody discovery method (hybridoma based, library based, single cell based, transgenic animal based, and others), animal model used (rabbit, rat, mouse, llama, chicken, transgenic animal and others), type of antibody discovered (monoclonal antibody, bispecific antibody, single domain antibody, antibody drug conjugate, antibody fragment and others) and purpose of antibody discovery (therapeutic and diagnostic).
  • An insightful competitiveness analysis of antibody discovery service providers, based on supplier strength (based on a company's employee count and years of experience) and service portfolio specifications, such as number of antibody discovery services offered, number of antibody discovery methods adopted, and number of subject specific agreements signed.
  • Elaborate profiles of antibody discovery service providers. Each company profile features a brief overview of the company, its financial information (if available), antibody discovery service portfolios and an informed future outlook.
  • A detailed review of the overall landscape of antibody discovery platforms, along with the information on the technology developers such as year of establishment, company size, location of headquarters and type of antibody discovered (monoclonal antibody, bispecific antibody, single domain antibody, antibody drug conjugate, antibody fragment and others). In addition, the chapter highlights an in-depth analysis of antibody discovery platforms based on type of antibody discovery method (hybridoma based, library-based, single cell-based, transgenic animal-based, and others), animal model used (rabbit, rat, mouse, llama, chicken, transgenic animal and others) and availability of intellectual property.
  • A detailed competitiveness analysis of antibody discovery platforms, taking into consideration the supplier power (based on the year of establishment of developer) and key technology specifications, such as type of antibody discovered, compatibility of antibodies in human (fully human or not), availability of patent protection, number of deals signed for a particular platform between 2015 and 2021.
  • Elaborate profiles of antibody discovery platform providers. Each company profile features a brief overview of the company, its financial information (if available), details on antibody discovery technology / platform(s) offered and an informed future outlook.
  • An assessment of antibody discovery service and platform providers' capability in different regions, based on a number of relevant parameters. For platform providers, these parameters include number of technologies offered, number of antibody discovery methods employed, and type of antibody discovered. On the other hand, the service providers have been evaluated based on the type(s) of service offered.
  • An analysis of the partnerships that have been established in this domain since 2015, covering R&D collaborations, licensing agreements, mergers and acquisitions, product development and / or commercialization agreements, clinical trial agreements, and other relevant deals.
  • An analysis of the investments made in this domain, during the period between 2016 and 2021, including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, in companies that are engaged in the field of antibody drug discovery.
  • Detailed profiles on the top five therapeutic antibody products, which have generated the highest revenues. Each profile features a brief overview of the drug, the type of antibody discovery method it employs and the annual historical sales of the product.
  • A case study on antibody humanization and affinity maturation, including a list of players that are presently offering such services and platforms, a publication analysis highlighting the research trends in this field and a detailed discussion on other affiliated trends, key drivers and challenges, under a comprehensive SWOT framework.
  • A brief discussion on the imminent opportunities (such as novel antibody therapeutics, innovative technologies and other future opportunities) in the field of drug discovery that are likely to impact the future evolution of this market over the coming years.
  • An analysis of the deal structure, highlighting cash flows and net present values of licensor and licensee, taking into consideration multiple likely scenarios of upfront, milestone and royalty payments.

One of the key objectives of the report was to estimate the existing market size and potential future opportunities for antibody discovery platforms and services, for the next decade. Based on parameters, such as the overall R&D expenditure available to CROs, percentage of R&D expenses incurred in each discovery step, and outsourcing profile, we have provided an informed estimate of the likely evolution of the antibody discovery services market in the mid to long term, for the time period 2021-2035. The report also features the likely distribution of the current and forecasted opportunity within antibody discovery services market across [A] the various steps involved in antibody discovery process (antigen designing, hit generation, lead selection, lead optimization and lead characterization), [B] antibody discovery methods (hybridoma based, library-based, single cell-based, transgenic animal-based, animal-based and others), [C] the nature of antibody generated (whether human/ fully human or not) and [D] key geographical regions (North America, Europe and Asia- Pacific and rest of the world). In addition, for estimating the future market opportunities for platform providers, we have considered the likely licensing deal structures and agreements that are expected to be inked in the foreseen future. The future opportunities within the antibody discovery platforms market has been segmented across key geographical regions (North America, Europe and Asia- Pacific). The opinions and insights presented in this study were influenced by inputs solicited via a comprehensive survey and discussions conducted with several key players in this domain. The report features detailed transcripts of interviews held with the following industry stakeholders:

  • Tracey Mullen (Chief Executive Officer, Abveris Antibody)
  • Lisa Delouise (Founder and Chief Technology Officer, Nidus Biosciences)
  • Mark Kubik (Chief Business Officer, AvantGen)
  • Chun-Nan Chen (Chief Executive Officer and Chief Scientific Officer, Single Cell Technology)
  • Giles Day (Co-Founder and Chief Executive Officer, Distributed Bio)
  • Kevin Heyries (Co-Founder and Lead of Business Development Strategy, AbCellera)
  • Sanjiban K Banerjee (Director, AbGenics Life Sciences)
  • Ignacio Pino (Chief Executive Officer and President, CDI Laboratories)
  • Jeng Her (Chief Executive Officer, AP Biosciences)
  • Thomas Schirrmann (Chief Executive Officer and General Manager, YUMAB)
  • Debra Valsamis (Business Development Associate, Antibody Solutions)
  • Christel Iffland (Vice President, Ligand Pharmaceuticals)
  • Aaron Sato (former Chief Scientific Officer, LakePharma)

All actual figures have been sourced and analyzed from publicly available information forums and inputs from primary research. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered:

  • Who are the leading industry players involved in offering services and technologies related to antibody discovery?
  • What is the relative competitiveness of the players offering services related to antibody discovery, based across different geographies?
  • What tis the relative competitiveness of the technologies pertaining to antibody discovery across different peer groups?
  • Which partnership models are commonly adopted by industry stakeholders offering services and technologies related to antibody discovery?
  • What is the trend for capital investments in the antibody discovery services and platforms market?
  • How is the current and future market opportunity related to antibody discovery services an platforms, likely to be distributed across key market segments?

Chapter Outlines:

Chapter 2 provides an executive summary of the insights captured in our research. It presents a high-level view on the current scenario within the antibody discovery services and platform market and its evolution in the short-mid-term and long term.

Chapter 3 provides a general introduction of antibodies featuring details on their historical background, structure, isotypes, mechanism of action and applications. It also emphasizes on the different types of antibodies, namely monoclonal, bispecific and polyclonal antibodies.

Chapter 4 features a detailed overview on the antibody discovery process and the various methods used in the discovery of these therapeutic biomolecules. It also highlights a comparison of different antibody discovery methods that are currently available. Additionally, the chapter provides insights on the gradual shift in development trends of monoclonal antibodies over the last three decades, tracking the transition from fully murine to fully human product variants.

Chapter 5 provides a general overview of the current market landscape of more than 80 service providers that are currently active in this domain. It features a detailed analysis of these players based on several parameters, such as year of establishment, company size, location of headquarters, type of service offered (antigen designing, hit generation, lead selection, and lead optimization and lead characterization), type of antibody discovery method (hybridoma based, library based, single cell based, transgenic animal based, and others), animal model used (rabbit, rat, mouse, llama, chicken, transgenic animal and others), type of antibody discovered (monoclonal antibody, bispecific antibody, single domain antibody, antibody drug conjugate, antibody fragment and others) and purpose of antibody discovery (therapeutic and diagnostic).

Chapter 6 provides an insightful competitiveness analysis of antibody discovery service providers that we came across during our research. The analysis compares the companies on the basis of supplier strength (based on the year of establishment of the service provider) and service strength (which takes into account the number of antibody discovery services offered, number of antibody discovery methods adopted, and number of subject specific agreements signed).

Chapter 7 provides detailed profiles of the stakeholders that are actively engaged in providing antibody discovery services to biopharmaceutical companies. Each company profile includes a brief overview of the company, its financial information (if available), details on antibody discovery services, recent developments and an informed future outlook.

Chapter 8 presents the current market landscape of over 120+ antibody discovery platform providers, including information on their company details such as year of establishment, company size, location of headquarters and type of antibody discovered (monoclonal antibody, bispecific antibody, single domain antibody, antibody drug conjugate, antibody fragment and others). In addition, the chapter highlights an in-depth analysis of 170+ antibody discovery platforms based on type of antibody discovery method (hybridoma based, library-based, single cell-based, transgenic animal-based, and others), animal model used (rabbit, rat, mouse, llama, chicken, transgenic animal and others) and availability of intellectual property.

Chapter 9 provides an insightful competitiveness analysis of antibody discovery platforms. It highlights the leading players in this domain, taking into consideration the supplier power (based on the year of establishment of the platform provider) and key specifications of the platforms, such as type of antibody discovered, compatibility of antibodies in human (fully human or not), availability of patent protection, number of deals signed for a particular platform (2015-2021).

Chapter 10 provides detailed profiles of the stakeholders, which actively provide access / licenses to their antibody discovery technology / platforms to other companies. Each company profile includes a brief overview of the company, its financial information (if available), details on antibody discovery technology / platforms, recent developments and an informed future outlook

Chapter 11 presents the antibody discovery capabilities in different regions, based on a number of relevant parameters, such as type of service offered for service providers, and number of technologies offered, number of antibody discovery methods and type of antibody discovered for platform providers.

Chapter 12 features an in-depth analysis and discussion on the various partnerships that have been inked between the players in this market in the time period between 2015 and 2021 (till November). It includes a brief description of partnership models (such as acquisitions, product development agreements, product integration agreements, commercialization agreements, clinical trial agreements, licensing agreements, manufacturing agreements, and service agreements) adopted by the stakeholders.

Chapter 13 presents an analysis of the investments made in this domain during the period 2016-2021 (till November), including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, at various stages of discovery in companies that are focused on antibody discovery.

Chapter 14 features an insightful market forecast analysis, highlighting the likely growth of antibody discovery services domain till the year 2035. In order to provide details on the future opportunities, our projections have been segmented on the basis of [A] the various steps involved in antibody discovery (antigen designing, hit generation, lead selection, lead optimization and lead characterization), [B] antibody discovery method (hybridoma based, library-based, single cell-based, transgenic animal-based, animal-based and others), [C] the nature of antibody generated (whether human/ fully human or not) and [D] key geographical regions (North America, Europe and Asia- Pacific and rest of the world).

Chapter 15 presents the likely growth of antibody discovery platform market, on the basis of licensing deal structures and agreements signed or planned in the foreseen future. In order to provide details on the future opportunities, the projections have been segmented on the basis of key geographical regions (North America, Europe and Asia- Pacific).

Chapter 16 provides deal structure analysis, highlighting cash flows and net present values of licensor and licensee, taking into consideration multiple likely scenarios of upfront, milestone and royalty payments.

Chapter 17 features detailed profiles of the most successful therapeutic monoclonal antibody products (as per sales reported in 2020). It provides information on top five drugs, namely Humira®, Keytruda®, Stelara®, Opdivo® and Avastin®, their historical sales, and discovery process and methods.

Chapter 18 features a case study on antibody humanization and affinity maturation, highlighting the importance of these methods in the process of antibody discovery and development. The chapter presents a list of key players along with the information on their respective location, their expertise across antibody humanization and / or affinity maturation, the methodology adopted for providing such services and the revenue / business models adopted by the players involved in this domain. In addition, chapter provides insights on a publication analysis representing the recent trends in research on antibody humanization across various academic institutes, highlighting the ongoing innovation in this domain. Further, the report features a detailed SWOT analysis, which elaborates on the various drivers and challenges that are likely to influence the activities of players engaged in this domain.

Chapter 19 provides an overview of future growth opportunities in the field of antibody discovery. The chapter discusses the upcoming antibody therapeutics and technologies, which are being developed / adopted by the antibody drug discovery service and platform providers that are likely to have influence on the industry's evolution over the coming decade.

Chapter 20 is a collection of interview transcripts of the discussions held with key stakeholders in this market. In this chapter, we have presented the details of our conversations with (in alphabetical order of person name) Tracey Mullen (Chief Executive Officer, Abveris Antibody), Lisa Delouise (Founder and Chief Technology Officer, Nidus Biosciences), Mark Kubik (Chief Business Officer, AvantGen), Chun-Nan Chen (Chief Executive Officer and Chief Scientific Officer, Single Cell Technology), Giles Day (Co-Founder and Chief Executive Officer, Distributed Bio), Kevin Heyries (Co-Founder and Lead of Business Development Strategy, AbCellera), Sanjiban K Banerjee (Director, AbGenics Life Sciences), Ignacio Pino (Chief Executive Officer and President, CDI Laboratories), Jeng Her (Chief Executive Officer, AP Biosciences), Thomas Schirrmann (Chief Executive Officer and General Manager, YUMAB), Debra Valsamis (Business Development Associate, Antibody Solutions), Christel Iffland (Vice President, Ligand Pharmaceuticals), Aaron Sato (Chief Scientific Officer, LakePharma / Twist Biosciences)

Chapter 21 summarizes the entire report, highlighting the various facts related to contemporary market trend and the likely evolution of the antibody discovery service and platform market.

Chapter 22 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 23 is an appendix, which contains the list of companies and organizations mentioned in the report.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Key Questions Answered
  • 1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Structure of Antibodies
  • 3.3. History of Antibody Development
  • 3.4. Antibody Isotypes
  • 3.5. Mechanism of Action of Antibodies
  • 3.6. Classification of Antibodies
    • 3.6.1. Monoclonal Antibodies
    • 3.6.2. Polyclonal Antibodies
    • 3.6.3. Bispecific Antibodies
  • 3.7. Applications of Antibodies
  • 3.8. Concluding Remarks

4. ANTIBODY DISCOVERY PROCESS AND METHODS

  • 4.1. Chapter Overview
  • 4.2. Antibody Discovery Process
    • 4.2.1. Target Selection and Validation
    • 4.2.2. Hit Generation
    • 4.2.3. Lead Selection
    • 4.2.4. Lead Optimization
      • 4.2.4.1. Humanization
      • 4.2.4.2. Affinity Maturation
      • 4.2.4.3. Fc Engineering
    • 4.2.5. Lead Characterization
    • 4.2.6. Candidate Selection
  • 4.3. Antibody Discovery Methods
    • 4.3.1. Hybridoma Technology-Based Method
    • 4.3.2. In vitro Display Method
      • 4.3.2.1. Phage Display
      • 4.3.2.2. Yeast Display
      • 4.3.2.3. Ribosomal Display
    • 4.3.3. Transgenic Animal-Based Method
    • 4.3.4. Single B Cell-Based Method
    • 4.3.5. Advantages and Disadvantages of Existing Antibody Discovery Techniques
  • 4.4. Evolution of Monoclonal Antibodies
    • 4.4.1. Fully Human Monoclonal Antibodies

5. ANTIBODY DISCOVERY SERVICE PROVIDERS: CURRENT MARKET LANDSCAPE

  • 5.1. Chapter Overview
  • 5.2. Antibody Discovery Service Providers: List of Industry Players
    • 5.2.1. Analysis by Year of Establishment
    • 5.2.2. Analysis by Company Size
    • 5.2.3. Analysis by Location of Headquarters
    • 5.2.4. Analysis by Type of Service Offered
    • 5.2.5. Analysis by Company Size and Type of Service Offered
    • 5.2.6. Analysis by Type of Antibody Discovery Method
    • 5.2.7. Grid Representation: Analysis by Type of Antibody Discovery Method, Type of Antibody Discovered and Location of Headquarters
    • 5.2.8. Analysis by Animal Model Used
    • 5.2.9. Analysis by Type of Antibody Discovered
    • 5.2.10. Analysis by Type of Antibody Discovery Method and Type of Antibody Discovered
    • 5.2.11. Analysis by Purpose of Antibody Discovery

6. COMPANY COMPETITIVENESS ANALYSIS

  • 6.1. Chapter Overview
  • 6.2. Methodology
  • 6.3. Key Parameters
  • 6.4. Competitiveness Analysis: Antibody Discovery Service Providers
    • 6.4.1. Antibody Discovery Service Providers based in North America
    • 6.4.2. Antibody Discovery Service Providers based in Europe
    • 6.4.3. Antibody Discovery Service Providers based in Asia-Pacific

7. COMPANY PROFILES: ANTIBODY DISCOVERY SERVICE PROVIDERS

  • 7.1. Chapter Overview
  • 7.2. Antibody Discovery Service Providers in North America
    • 7.2.1. Abwiz Bio
      • 7.2.1.1. Company Overview
      • 7.2.1.2. Antibody Discovery Services Portfolio
      • 7.2.1.3. Recent Developments and Future Outlook
    • 7.2.2. Aragen Bioscience (a GVK BIO company)
      • 7.2.2.1. Company Overview
      • 7.2.2.2. Antibody Discovery Services Portfolio
      • 7.2.2.3. Recent Developments and Future Outlook
    • 7.2.3. Creative Biolabs
      • 7.2.3.1. Company Overview
      • 7.2.3.2. Antibody Discovery Services Portfolio
      • 7.2.3.3. Recent Developments and Future Outlook
    • 7.2.4. Distributed Bio
      • 7.2.4.1. Company Overview
      • 7.2.4.2. Antibody Discovery Services Portfolio
      • 7.2.4.3. Recent Developments and Future Outlook
    • 7.2.5. ImmunoPrecise Antibodies
      • 7.2.5.1. Company Overview
      • 7.2.5.2. Financial Information
      • 7.2.5.3. Antibody Discovery Services Portfolio
      • 7.2.5.4. Recent Developments and Future Outlook
    • 7.2.6. Integral Molecular
      • 7.2.6.1. Company Overview
      • 7.2.6.2. Antibody Discovery Services Portfolio
      • 7.2.6.3. Recent Developments and Future Outlook
    • 7.2.7. LakePharma
      • 7.2.7.1. Company Overview
      • 7.2.7.2. Antibody Discovery Services Portfolio
      • 7.2.7.3. Recent Developments and Future Outlook
    • 7.2.8. Syd Labs
      • 7.2.8.1. Company Overview
      • 7.2.8.2. Antibody Discovery Services Portfolio
  • 7.3. Antibody Discovery Service Providers in Europe
    • 7.3.1. Abzena
      • 7.3.1.1. Company Overview
      • 7.3.1.2. Financial Information
      • 7.3.1.3. Antibody Discovery Services Portfolio
      • 7.3.1.4. Recent Developments and Future Outlook
    • 7.3.2. BIOTEM
      • 7.3.2.1. Company Overview
      • 7.3.2.2. Antibody Discovery Services Portfolio
      • 7.3.2.3. Recent Developments and Future Outlook
    • 7.3.3. PX'Therapeutics (Subsidiary of Aguettant Pharmaceutical Group)
      • 7.3.3.1. Company Overview
      • 7.3.3.2. Antibody Discovery Services Portfolio
      • 7.3.3.3. Recent Developments and Future Outlook
  • 7.4. Antibody Discovery Service Providers in Asia-Pacific
    • 7.4.1. ChemPartner
      • 7.4.1.1. Company Overview
      • 7.4.1.2. Antibody Discovery Services Portfolio
      • 7.4.1.3. Recent Developments and Future Outlook
    • 7.4.2. HD Biosciences
      • 7.4.2.1. Company Overview
      • 7.4.2.2. Antibody Discovery Services Portfolio
    • 7.4.3. Viva Biotech
      • 7.4.3.1. Company Overview
      • 7.4.3.2. Financial Information
      • 7.4.3.3. Antibody Discovery Services Portfolio
      • 7.4.3.4. Recent Developments and Future Outlook
    • 7.4.4. WuXi Biologics
      • 7.4.4.1. Company Overview
      • 7.4.4.2. Financial Information
      • 7.4.4.3. Antibody Discovery Services Portfolio
      • 7.4.4.4. Recent Developments and Future Outlook

8. ANTIBODY DISCOVERY TECHNOLOGIES: CURRENT MARKET LANDSCAPE

  • 8.1. Chapter Overview
  • 8.2. Antibody Discovery Platform Providers: List of Industry Players
    • 8.2.1. Analysis by Year of Establishment
    • 8.2.2. Analysis by Company Size
    • 8.2.3. Analysis by Location of Headquarters
    • 8.2.4. Analysis by Type of Antibody Discovered
  • 8.3. Antibody Discovery: List of Technologies and Platforms
    • 8.3.1. Analysis by Type of Antibody Discovery Method
    • 8.3.2. Analysis by Type of Antibody Discovery Method and Location of Headquarters
    • 8.3.3. Analysis by Animal Model Used
    • 8.3.4. Analysis by Patent Availability

9. TECHNOLOGY COMPETITIVENESS ANALYSIS

  • 9.1. Chapter Overview
  • 9.2. Methodology
  • 9.3. Library based Antibody Discovery Platforms
    • 9.3.1. Key Assumptions and Parameters
    • 9.3.2. Technology Competitiveness Analysis
  • 9.4. Single Cell based Antibody Discovery Platforms
    • 9.4.1 Key Assumptions and Parameters
    • 9.4.2. Technology Competitiveness Analysis
  • 9.5. Transgenic Animal based Antibody Discovery Platforms
    • 9.5.1. Key Assumptions and Parameters
    • 9.5.2. Technology Competitiveness Analysis
  • 9.6. Hybridoma based Antibody Discovery Platforms
    • 9.6.1. Key Assumptions and Parameters
    • 9.6.2. Technology Competitiveness Analysis
  • 9.7. Other Antibody Discovery Platforms
    • 9.7.1. Key Assumptions and Parameters
    • 9.7.2. Technology Competitiveness Analysis

10. COMPANY PROFILES: ANTIBODY DISCOVERY PLATFORM PROVIDERS

  • 10.1. Chapter Overview
  • 10.2. Harbour BioMed
    • 10.2.1. Company Overview
    • 10.2.2. Antibody Discovery Platforms Portfolio
      • 10.2.2.1. H2L2 Platform
      • 10.2.2.2. HCAb Platform
    • 10.2.3. Recent Developments and Future Outlook
  • 10.3. ImmunoPrecise Antibodies
    • 10.3.1. Company Overview
    • 10.3.2. Financial Information
    • 10.3.3. Antibody Discovery Platforms Portfolio
      • 10.3.3.1. Abthena™
      • 10.3.3.2. B cell Select™
      • 10.3.3.3. DeepDisplay™
      • 10.3.3.4. ModiFuse™
      • 10.3.3.5. ModiPhage™
      • 10.3.3.6. ModiSelect™
      • 10.3.3.7. ModiTune™
    • 10.3.4. Recent Developments and Future Outlook
  • 10.4. Kymab
    • 10.4.1. Company Overview
    • 10.4.2. Antibody Discovery Platforms Portfolio
      • 10.4.2.1. Kymouse™
      • 10.4.2.2. IntelliSelect®
    • 10.4.3. Recent Developments and Future Outlook
  • 10.5. Ligand Pharmaceuticals
    • 10.5.1. Company Overview
    • 10.5.2. Financial Information
    • 10.5.3. Antibody Discovery Platforms Portfolio
      • 10.5.3.1. OmniAb®
        • 10.5.3.1.1. OmniChicken®
        • 10.5.3.1.2. OmniClic™
        • 10.5.3.1.3. OmniFlic®
        • 10.5.3.1.4. OmniMouse®
        • 10.5.3.1.5. OmniRat®
    • 10.5.4. Recent Developments and Future Outlook
  • 10.6. MorphoSys
    • 10.6.1. Company Overview
    • 10.6.2. Financial Information
    • 10.6.3. Antibody Discovery Platforms Portfolio
      • 10.6.3.1. arYla® Technology
      • 10.6.3.2. HuCAL® Technology
      • 10.6.3.3. Ylanthia® Technology
    • 10.6.4. Recent Developments and Future Outlook

11. REGIONAL CAPABILITY ANALYSIS

  • 11.1. Chapter Overview
  • 11.2. Key Assumptions and Methodology
  • 11.3. Regional Capability Analysis: Antibody Discovery Service Providers
    • 11.3.1 Regional Capability Analysis: Antibody Discovery Service Providers in North America
    • 11.3.2. Regional Capability Analysis: Antibody Discovery Service Providers in Europe
    • 11.3.3. Regional Capability Analysis: Antibody Discovery Service Providers in Asia-Pacific
  • 11.4. Regional Capability Analysis: Antibody Discovery Platform Providers
    • 11.4.1. Regional Capability Analysis: Distribution of Antibody Discovery Platform Providers in North America
    • 11.4.2. Regional Capability Analysis: Distribution of Antibody Discovery Platform Providers in Europe
    • 11.4.3. Regional Capability Analysis: Distribution of Antibody Discovery Platform Providers in Asia-Pacific
  • 11.5. Concluding Remarks

12. PARTNERSHIPS AND COLLABORATIONS

  • 12.1. Chapter Overview
  • 12.2. Partnership Models
  • 12.3. List of Partnerships and Collaborations
    • 12.3.1. Analysis by Year of Partnership
    • 12.3.2. Analysis by Type of Partnership
    • 12.3.3. Analysis by Type of Company (Service / Platform Providers)
    • 12.3.4. Analysis by Type of Antibody Discovered
    • 12.3.5. Analysis by Year of Partnership and Type of Partner
    • 12.3.6. Analysis by Type of Partnership and Type of Partner
    • 12.3.7. Most Active Players: Analysis by Number of Partnerships
    • 12.3.8. Most Popular Technologies: Analysis by Number of Partnerships
    • 12.3.9. Regional Analysis
      • 12.3.9.1. Intercontinental and Intracontinental Agreements

13. FUNDING AND INVESTMENT ANALYSIS

  • 13.1. Chapter Overview
  • 13.2. Types of Funding
  • 13.3. Antibody Discovery Service and Platform Providers: Funding and Investment Analysis
    • 13.3.1. Analysis by Number of Funding Instances
    • 13.3.2. Analysis by Amount Invested
    • 13.3.3. Analysis by Type of Funding
    • 13.3.4. Most Active Players: Analysis by Amount Invested
    • 13.3.5. Most Active Investors: Analysis by Number of Funding Instances
    • 13.3.6. Regional Analysis by Amount Invested
  • 13.4. Concluding Remarks

14. ANTIBODY DISCOVERY SERVICES: MARKET FORECAST

  • 14.1. Chapter Overview
  • 14.2. Forecast Methodology
  • 14.3. Global Antibody Discovery Services Market, 2021-2035
  • 14.4. Global Antibody Discovery Services Market: Distribution by Steps Involved in Antibody Discovery Process, 2021-2035
    • 14.4.1. Antibody Discovery Services Market for Antigen Designing, 2021-2035
    • 14.4.2. Antibody Discovery Services Market for Hit Generation, 2021-2035
    • 14.4.3. Antibody Discovery Services Market for Lead Selection, 2021-2035
    • 14.4.4. Antibody Discovery Services Market for Lead Optimization, 2021-2035
    • 14.4.5. Antibody Discovery Services Market for Lead Characterization, 2021-2035
  • 14.5. Global Antibody Discovery Services Market: Distribution by Antibody Discovery Method, 2021-2035
    • 14.5.1. Antibody Discovery Services Market for Phage Display, 2021-2035
    • 14.5.2. Antibody Discovery Services Market for Yeast Display, 2021-2035
    • 14.5.3. Antibody Discovery Services Market for Hybridoma Method, 2021-2035
    • 14.5.4. Antibody Discovery Services Market for Transgenic Animal Based Method, 2021-2035
    • 14.5.5. Antibody Discovery Services Market for Single Cell Based Method, 2021-2035
    • 14.5.6. Antibody Discovery Services Market for Other Methods, 2021-2035
  • 14.6. Global Antibody Discovery Services Market: Distribution by Nature of Antibody Generated, 2021-2035
    • 14.6.1. Antibody Discovery Services Market for Humanized Antibodies, 2021-2035
    • 14.6.2. Antibody Discovery Services Market for Human Antibodies, 2021-2035
    • 14.6.3. Antibody Discovery Services Market for Chimeric Antibodies, 2021-2035
    • 14.6.4. Antibody Discovery Services Market for Murine Antibodies, 2021-2035
  • 14.7. Global Antibody Discovery Services Market: Distribution by Region, 2021-2035
    • 14.7.1. Antibody Discovery Services Market in North America, 2021-2035
    • 14.7.2. Antibody Discovery Services Market in Europe, 2021-2035
    • 14.7.3. Antibody Discovery Services Market in Asia-Pacific and Rest of the World, 2021-2035
    • 14.7.4. Antibody Discovery Services: Market Attractiveness Analysis by Region

15. ANTIBODY DISCOVERY TECHNOLOGIES: MARKET FORECAST

  • 15.1. Chapter Overview
  • 15.2. Key Assumptions
  • 15.3. Forecast Methodology
  • 15.4. Global Antibody Discovery Platforms Market, 2021-2035
  • 15.5. Global Antibody Discovery Platforms Market: Distribution by Region, 2021-2035
    • 15.5.1. Antibody Discovery Platforms Market in North America, 2021-2035
    • 15.5.2. Antibody Discovery Platforms Market in Europe, 2021-2035
    • 15.5.3. Antibody Discovery Platforms Market in Asia-Pacific, 2021-2035

16. LICENSING DEAL STRUCTURE

17. CASE IN POINT: DRUG DISCOVERY PROCESSES OF TOP SELLING ANTIBODIES

  • 17.1. Chapter Overview
  • 17.2. Humira® (Adalimumab)
    • 17.2.1. Drug Overview
    • 17.2.2. Discovery Process and Method
    • 17.2.3. Historical Sales
  • 17.3. Keytruda® (Pembrolizumab)
    • 17.3.1. Drug Overview
    • 17.3.2. Discovery Process and Method
    • 17.3.3. Historical Sales
  • 17.4. Stelara® (Ustekinumab)
    • 17.4.1. Drug Overview
    • 17.4.2. Discovery Process and Method
    • 17.4.3. Historical Sales
  • 17.5. Opdivo® (Nivolumab)
    • 17.5.1. Drug Overview
    • 17.5.2. Discovery Process and Method
    • 17.5.3. Historical Sales
  • 17.6. Avastin® (Bevacizumab)
    • 17.6.1. Drug Overview
    • 17.6.2. Discovery Process and Method
    • 17.6.3. Historical Sales

18. CASE STUDY: ANTIBODY HUMANIZATION AND AFFINITY MATURATION

  • 18.1. Importance of Antibody Humanization and Affinity Maturation
  • 18.2. Antibody Humanization and Affinity Maturation Service and Platform Providers: Market Landscape
  • 18.3. Antibody Humanization: Publication Analysis
    • 18.3.1. Publication Analysis: Year-Wise Trend
    • 18.3.2. Publication Analysis: Key Journals
    • 18.3.3. Publication Analysis: Distribution by Animal Model Used
    • 18.3.4. Publication Analysis: Distribution by Antibody Humanization Method
  • 18.4. Antibody Humanization Service and Platform Providers: SWOT Analysis

19. FUTURE GROWTH OPPORTUNITIES IN ANTIBODY DISCOVERY

  • 19.1. Chapter Overview
  • 19.2. Anticipated Shift from Monoclonal Antibodies to Other Novel Antibody Formats
  • 19.3. Technological Advancements to Overhaul Conventional Antibody Discovery Processes
  • 19.4. Transition to CADD-based Approaches to Help Achieve Better Operational Efficiencies
  • 19.5. Rising Demand for Antibody-based Treatment Options for Non-Oncological Indications
  • 19.6. Future Growth Opportunities in the Asia-Pacific Region
  • 19.7. Expected Increase in Number of Collaborations and Licensing Activity
  • 19.8 Concluding Remarks

20. CONCLUDING REMARKS

  • 20.1. Chapter Overview

21. EXECUTIVE INSIGHTS

  • 21.1. Chapter Overview
  • 21.2. Abveris Antibody
    • 21.2.1. Company Snapshot
    • 21.2.2. Tracey Mullen, Chief Executive Officer (Q2 2020)
  • 21.3. Nidus Biosciences
    • 21.3.1. Company Snapshot
    • 21.3.2. Lisa Delouise, Founder and Chief Technology Officer (Q1 2020)
  • 21.4. AvantGen
    • 21.4.1. Company Snapshot
    • 21.4.2. Mark Kubik, Chief Business Officer(Q1 2020)
  • 21.5. Single Cell Technology
    • 21.5.1. Company Snapshot
    • 21.5.2. Chun-Nan Chen, Chief Executive Officer and Chief Scientific Officer (Q2 2018)
  • 21.6. Distributed Bio
    • 21.6.1. Company Snapshot
    • 21.6.2. Giles Day, Co-Founder and Chief Executive Officer (Q2 2018)
  • 21.7. AbCellera
    • 21.7.1. Company Snapshot
    • 21.7.2. Kevin Heyries, Co-Founder and Lead of Business Development Strategy (Q2 2018)
  • 21.8. AbGenics Life Sciences
    • 21.8.1. Company Snapshot
    • 21.8.2. Sanjiban K Banerjee, Director (Q2 2018)
  • 21.9. CDI Laboratories
    • 21.9.1. Company Snapshot
    • 21.9.2. Ignacio Pino, Chief Executive Officer and President (Q2 2017)
  • 21.10. AP Biosciences
    • 21.10.1. Company Snapshot
    • 19.10.2. Jeng Her, Chief Executive Officer (Q2 2017)
  • 21.11. YUMAB
    • 21.11.1. Company Snapshot
    • 21.11.2. Thomas Schirrmann, Chief Executive Officer and General Manager (Q2 2017)
  • 21.12. Antibody Solutions
    • 21.12.1. Company Snapshot
    • 21.12.2. Debra Valsamis, Business Development Associate (Q2 2017)
  • 21.13. Ligand Pharmaceuticals
    • 21.13.1. Company Snapshot
    • 21.13.2. Christel Iffland, Vice President (Q2 2017)
  • 21.14. LakePharma
    • 21.14.1. Company Snapshot
    • 21.14.2. Aaron Sato, Chief Scientific Officer (Q2 2017)

22. APPENDIX 1: TABULATED DATA

23. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATION

List Of Figures

  • Figure 3.1 Basic Structure of an Antibody
  • Figure 3.2 Historical Timeline of Antibody Development
  • Figure 3.3 Mechanism of Action of Antibodies
  • Figure 3.4 Applications of Antibodies
  • Figure 4.1 Overview of the Antibody Discovery Process
  • Figure 4.2 Antibody Discovery Process: Hybridoma Method
  • Figure 4.3 Antibody Discovery Process: Phage Display Method
  • Figure 4.4 Antibody Generation Using Transgenic Animals
  • Figure 4.5 Approved Monoclonal Antibodies: Development Trend Analysis
  • Figure 4.6 Approval Timeline of Fully Human Monoclonal Antibodies
  • Figure 4.7 Discovery Methods of Fully Human Monoclonal Antibodies
  • Figure 5.1 Antibody Discovery Service Providers: Distribution by Year of Establishment
  • Figure 5.2 Antibody Discovery Service Providers: Distribution by Company Size
  • Figure 5.3 Antibody Discovery Service Providers: Distribution by Location of Headquarters
  • Figure 5.4 World Map Representation: Distribution by Location by Headquarters
  • Figure 5.5 Antibody Discovery Service Providers: Distribution by Type of Service Offered
  • Figure 5.6 Antibody Discovery Service Providers: Distribution by Company Size and Type of Service Offered
  • Figure 5.7 Antibody Discovery Service Providers: Distribution by Type of Antibody Discovery Method
  • Figure 5.8 Grid Representation: Distribution by Type of Antibody Discovery Method, Type of Antibody Discovered and Location of Headquarters
  • Figure 5.9 Antibody Discovery Service Providers: Distribution by Animal Model Used
  • Figure 5.10 Antibody Discovery Service Providers: Distribution by Type of Antibody Discovered
  • Figure 5.11 Antibody Discovery Service Providers: Distribution by Type of Antibody Discovery Method and Type of Antibody Discovered
  • Figure 5.12 Antibody Discovery Service Providers: Distribution by Purpose of Antibody Discovery
  • Figure 6.1 Competitiveness Analysis: Antibody Discovery Service Providers based in North America
  • Figure 6.2 Competitiveness Analysis: Antibody Discovery Service Providers based in Europe
  • Figure 6.3 Competitiveness Analysis: Antibody Discovery Service Providers based in Asia-Pacific
  • Figure 7.1 Abzena: Annual Revenues, 2014-2018 (GBP Million)
  • Figure 7.2 ImmunoPrecise Antibodies: Annual Revenues, 2016-2021 (USD Million)
  • Figure 7.3 Viva Biotech: Annual Revenues, 2016-H1 2021 (RMB Million)
  • Figure 7.4 WuXi Biologics: Annual Revenues, 2015-H1 2021 (RMB Billion)
  • Figure 8.1 Antibody Discovery Platform Providers: Distribution by Year of Establishment
  • Figure 8.2 Antibody Discovery Platform Providers: Distribution by Company Size
  • Figure 8.3 Antibody Discovery Platform Providers: Distribution by Location of Headquarters
  • Figure 8.4 World Map Representation: Distribution by Location by Headquarters
  • Figure 8.5 Antibody Discovery Platform Providers: Distribution by Type of Antibody Discovered
  • Figure 8.6 Antibody Discovery Platforms: Distribution by Type of Antibody Discovery Method
  • Figure 8.7 Antibody Discovery Platforms: Distribution by Type of Antibody Discovery Method and Location of Headquarters
  • Figure 8.8 Antibody Discovery Platforms: Distribution by Animal Model Used
  • Figure 8.9 Antibody Discovery Platforms: Distribution by Patent Availability
  • Figure 9.1 Competitiveness Analysis: Library based Antibody Discovery Platforms
  • Figure 9.2 Competitiveness Analysis: Single Cell based Antibody Discovery Platforms
  • Figure 9.3 Competitiveness Analysis: Transgenic Animal based Antibody Discovery Platforms
  • Figure 9.4 Competitiveness Analysis: Hybridoma based Antibody Discovery Platforms
  • Figure 9.5 Competitiveness Analysis: Other Antibody Discovery Platforms
  • Figure 10.1 ImmunoPrecise Antibodies: Annual Revenues, 2016-2021 (USD Million)
  • Figure 10.2 Ligand Pharmaceuticals: Annual Revenues, 2014-9M 2021 (USD Million)
  • Figure 10.3 MorphoSys: Annual Revenues, 2014-9M 2021 (USD Million)
  • Figure 11.1 Regional Capability Analysis: Antibody Discovery Service Providers based in North America
  • Figure 11.2 Regional Capability Analysis: One-Stop Shops in North America
  • Figure 11.3 Regional Capability Analysis: Antibody Discovery Service Providers based in Europe
  • Figure 11.4 Regional Capability Analysis: One-Stop Shops in Europe
  • Figure 11.5 Regional Capability Analysis: Antibody Discovery Service Providers based in Asia-Pacific
  • Figure 11.6 Regional Capability Analysis: One-Stop Shops in Asia-Pacfic
  • Figure 11.7 Regional Capability Analysis: Concluding Remarks
  • Figure 12.1 Partnerships and Collaborations: Cumulative Trend by Year, 2015-2021
  • Figure 12.2 Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 12.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2015-2020
  • Figure 12.4 Partnerships and Collaborations: Distribution by Type of Company (Service / Platform Providers)
  • Figure 12.5 Partnerships and Collaborations: Distribution by Type of Antibody Discovered
  • Figure 12.6 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
  • Figure 12.7 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
  • Figure 12.8 Most Active Players: Distribution by Number of Partnerships
  • Figure 12.9 Most Popular Technologies: Distribution by Number of Partnerships
  • Figure 12.10 Partnerships and Collaborations: Regional Distribution
  • Figure 12.11 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
  • Figure 13.1 Funding and Investment Analysis: Distribution by Type of Funding and Year of Establishment
  • Figure 13.2 Funding and Investment Analysis: Cumulative Year-wise Distribution of Funding Instances, 2016-2021
  • Figure 13.3 Funding and Investment Analysis: Year-wise Distribution of Funding Instances by Type of Company, (2016-2021)
  • Figure 13.4 Funding and Investment Analysis: Distribution by Cumulative Amount Invested, 2016-2021 (USD Million)
  • Figure 13.5 Funding and Investment Analysis: Year-wise Distribution of Funding Instances by Amount Invested, 2016-2021 (USD Million)
  • Figure 13.6 Funding and Investment Analysis: Year-wise Distribution of the Amount Raised by Type of Company, 2016-2021 (USD Million)
  • Figure 13.7 Funding and Investment Analysis: Distribution of Instances by Type of Funding,
  • Figure 13.8 Funding and Investment Analysis: Distribution of Type of Funding and Amount Invested, (USD Million)
  • Figure 13.9 Most Active Player: Distribution by Number of Funding Instances
  • Figure 13.10 Most Active Player: Distribution by Total Amount Invested (USD Million)
  • Figure 13.11 Most Active Investors: Distribution by Number of Funding Instances
  • Figure 13.12 Funding and Investment Analysis: Distribution by Geography
  • Figure 13.13 Funding and Investment Analysis: Regional Distribution of Funding Instances
  • Figure 13.14 Funding and Investment Summary
  • Figure 14.1 Global Antibody Discovery Services Market, 2021-2035 (USD Billion)
  • Figure 14.2 Global Antibody Discovery Services Market: Distribution by Steps Involved in Antibody Discovery Process, 2021-2035 (USD Billion)
  • Figure 14.3 Antibody Discovery Services Market for Antigen Designing, 2021-2035 (USD Billion)
  • Figure 14.4 Antibody Discovery Services Market for Hit Generation, 2021-2035 (USD Billion)
  • Figure 14.5 Antibody Discovery Services Market for Lead Selection, 2021-2035 (USD Billion)
  • Figure 14.6 Antibody Discovery Services Market for Lead Optimization, 2021-2035 (USD Billion)
  • Figure 14.7 Antibody Discovery Services Market for Lead Characterization, 2021-2035 (USD Billion)
  • Figure 14.8 Global Antibody Discovery Services Market: Distribution by Antibody Discovery Method, 2021-2035 (USD Billion)
  • Figure 14.9 Antibody Discovery Services Market for Phage Display, 2021-2035 (USD Billion)
  • Figure 14.10 Antibody Discovery Services Market for Yeast Display, 2021-2035 (USD Billion)
  • Figure 14.11 Antibody Discovery Services Market for Hybridoma Method, 2021-2035 (USD Billion)
  • Figure 14.12 Antibody Discovery Services Market for Transgenic Animal based Method, 2021-2035 (USD Billion)
  • Figure 14.13 Antibody Discovery Services Market for Single Cell based Method, 2021-2035 (USD Billion)
  • Figure 14.14 Antibody Discovery Services Market for Other Methods, 2021-2035 (USD Billion)
  • Figure 14.15 Global Antibody Discovery Services Market: Distribution by Nature of Antibody Generated, 2021-2035 (USD Billion)
  • Figure 14.16 Antibody Discovery Services Market for Humanized Antibodies, 2021-2035 (USD Billion)
  • Figure 14.17 Antibody Discovery Services Market for Human Antibodies, 2021-2035 (USD Billion)
  • Figure 14.18 Antibody Discovery Services Market for Chimeric Antibodies, 2021-2035 (USD Billion)
  • Figure 14.19 Antibody Discovery Services Market for Murine Antibodies, 2021-2035 (USD Billion)
  • Figure 14.20 Global Antibody Discovery Services Market: Distribution by Region, 2021-2035 (USD Billion)
  • Figure 14.21 Antibody Discovery Services Market in North America, 2021-2035 (USD Billion)
  • Figure 14.22 Antibody Discovery Services Market in Europe, 2021-2035 (USD Billion)
  • Figure 14.23 Antibody Discovery Services Market in Asia-Pacific and Rest of the World, 2021-2035 (USD Billion)
  • Figure 14.24 Antibody Discovery Services: Market Attractiveness Analysis by Region (USD Billion)
  • Figure 15.1 Licensing Agreements: Distribution of Financial Components
  • Figure 15.2 Technology Licensing Deal: Payment Structure
  • Figure 15.3 Global Antibody Discovery Platforms Market, 2021-2035 (USD Million)
  • Figure 15.4 Global Antibody Discovery Platforms Market: Distribution by Region, 2021-2035 (USD Million)
  • Figure 15.5 Antibody Discovery Platforms Market in North America, 2021-2035 (USD Million)
  • Figure 15.6 Antibody Discovery Platforms Market in Europe, 2021-2035 (USD Million)
  • Figure 15.7 Antibody Discovery Platforms Market in Asia-Pacific, 2021-2035 (USD Million)
  • Figure 16.1 Humira®: Annual Sales, 2016-9M 2021 (USD Billion)
  • Figure 16.2 Keytruda®: Annual Sales, 2016-9M 2021 (USD Billion)
  • Figure 16.3 Stelara®: Annual Sales, 2016-9M 2021 (USD Billion)
  • Figure 16.4 Opdivo®: Annual Sales, 2016-9M 2021 (USD Billion)
  • Figure 16.5 Avastin®: Annual Sales, 2016-9M 2021 (CHF Million)
  • Figure 17.1 Publication Analysis: Year-wise Distribution of Publications, 2014-2017
  • Figure 17.2 Publication Analysis: Distribution by Key Journals
  • Figure 17.3 Publication Analysis: Distribution by Animal Model Used
  • Figure 17.4 Publication Analysis: Distribution by Antibody Humanization Method Used
  • Figure 17.6 Antibody Humanization Service and Platform Providers: SWOT Analysis
  • Figure 17.7 Antibody Humanization Service and Platform Providers: Strengths Overview
  • Figure 17.8 Antibody Humanization Service and Platform Providers: Weaknesses Overview
  • Figure 17.9 Antibody Humanization Service and Platform Providers: Opportunities Overview
  • Figure 17.10 Antibody Humanization Service and Platform Providers: Threats Overview
  • Figure 18.1 Future Opportunities Related to Upcoming Trends in Drug Discovery
  • Figure 18.2 Number of Licensing Deals, 2015- 2021

List Of Tables

  • Table 3.1 Antibody Isotypes: Key Features
  • Table 3.2 Mechanism of Action of Therapeutic Antibodies against Different Target Classes
  • Table 3.3 Differences Between Polyclonal and Monoclonal Antibodies
  • Table 4.1 Antibody Discovery Methods: Advantages and Disadvantages
  • Table 4.2 List of Approved Monoclonal Antibodies
  • Table 5.1 List of Antibody Discovery Service Providers
  • Table 5.2 Antibody Discovery Service Providers: Information on Type of Service(s) Offered
  • Table 5.3 Antibody Discovery Service Providers: Information on Type of Antibody Discovery Method(s)
  • Table 5.4 Antibody Discovery Service Providers: Information on Animal Model Used
  • Table 5.5 Antibody Discovery Service Providers: Information on Type of Antibody Discovered
  • Table 5.6 Antibody Discovery Service Providers: Information on Purpose of Antibody Discovery
  • Table 7.1 Antibody Discovery Service Providers: List of Companies Profiled
  • Table 7.2 Abwiz Bio: Recent Developments and Future Outlook
  • Table 7.3 Aragen Bioscience: Recent Developments and Future Outlook
  • Table 7.4 Creative Biolabs: Recent Developments and Future Outlook
  • Table 7.4 Distributed Bio: Recent Developments and Future Outlook
  • Table 7.5 ImmunoPrecise Antibodies: Recent Developments and Future Outlook
  • Table 7.6 Integral Molecular: Recent Developments and Future Outlook
  • Table 7.7 LakePharma: Recent Developments and Future Outlook
  • Table 7.8 Abzena: Recent Developments and Future Outlook
  • Table 7.9 BIOTEM: Recent Developments and Future Outlook
  • Table 7.10 PX'Therapeutics: Recent Developments and Future Outlook
  • Table 7.11 ChemPartner: Recent Developments and Future Outlook
  • Table 7.12 Viva Biotech: Recent Developments and Future Outlook
  • Table 7.13 WuXi Biologics: Recent Developments and Future Outlook
  • Table 8.1 List of Antibody Discovery Platform Providers
  • Table 8.2 Antibody Discovery Platform Providers: Information on Type of Antibody Discovered
  • Table 8.3 Antibody Discovery: List of Technologies and Platforms
  • Table 8.4 Antibody Discovery Platforms: Information on Type of Antibody Discovery Method(s)
  • Table 8.5 Antibody Discovery Platforms: Information on Animal Model Used
  • Table 8.6 Antibody Discovery Platforms: Information on Patent Availability
  • Table 10.1 Antibody Discovery Platform Providers: List of Companies Profiled
  • Table 10.2 Harbour BioMed: Recent Developments and Future Outlook
  • Table 10.3 ImmunoPrecise Antibodies: Recent Developments and Future Outlook
  • Table 10.4 Kymab: Recent Developments and Future Outlook
  • Table 10.5 OmniAb® Technology: Patent Information
  • Table 10.6 OmniChicken® Technology: Patent Information
  • Table 10.7 Ligand Pharmaceuticals: Recent Developments and Future Outlook
  • Table 10.8 MorphoSys: Recent Developments and Future Outlook
  • Table 11.1 Regional Capability Analysis: Antibody Discovery Platform Providers based in North America
  • Table 11.2 Regional Capability Analysis: Antibody Discovery Platform Providers based in Europe
  • Table 11.3 Regional Capability Analysis: Antibody Discovery Platform Providers based in Asia-Pacific
  • Table 12.1 Antibody Discovery Service and Platform Providers: List of Partnerships and Collaboration, 2015-2021
  • Table 13.1 Antibody Discovery Service and Platform Providers: List of Funding Instances, 2016-2021
  • Table 13.2 Funding and Investment Analysis: Summary of Investments
  • Table 15.1 Developmental / Regulatory Milestones
  • Table 15.2 Antibody Discovery Platforms: Average Upfront and Average Milestone Payments (USD Million)
  • Table 16.1 List of Top Ten Selling Therapeutic Antibodies, 2020
  • Table 17.1 Approved Monoclonal Antibodies: Information on Affinity
  • Table 17.2 Antibody Humanization and Affinity Maturation: Service and Platform Providers
  • Table 17.3 Antibody Humanization and Affinity Maturation: Methods Employed by Service and Platform Providers
  • Table 17.4 Antibody Humanization: List of Recent Publications
  • Table 17.5 Antibody Humanization: Modified CDR Grafting Methods
  • Table 18.1 Antibody Discovery Services and Platform Providers: Asia-Pacific Region
  • Table 19.1 Abveris Antibody: Company Snapshot
  • Table 19.2 Nidus Biosciences: Company Snapshot
  • Table 19.3 AvantGen: Company Snapshot
  • Table 19.4 Single Cell Technology: Company Snapshot
  • Table 19.5 Distributed Bio: Company Snapshot
  • Table 19.6 AbCellera: Company Snapshot
  • Table 19.7 AbGenics Life Sciences: Company Snapshot
  • Table 19.8 CDI Laboratories: Company Snapshot
  • Table 19.9 AP Biosciences: Company Snapshot
  • Table 19.10 YUMAB: Company Snapshot
  • Table 19.12 Antibody Solutions: Company Snapshot
  • Table 19.13 Ligand Pharmaceuticals: Company Snapshot
  • Table 19.14 LakePharma: Company Snapshot
  • Table 21.1 Antibody Discovery Service Providers: Distribution by Year of Establishment
  • Table 21.2 Antibody Discovery Service Providers: Distribution by Company Size
  • Table 21.3 Antibody Discovery Service Providers: Distribution by Location of Headquarters
  • Table 21.4 Antibody Discovery Service Providers: Distribution by Type of Service Offered
  • Table 21.5 Antibody Discovery Service Providers: Distribution by Type of Antibody Discovery Method
  • Table 21.6 Antibody Discovery Service Providers: Distribution by Animal Model Used
  • Table 21.7 Antibody Discovery Service Providers: Distribution by Type of Antibody Discovered
  • Table 21.8 Antibody Discovery Service Providers: Distribution by Purpose of Antibody Discovery
  • Table 21.9 Abzena: Annual Revenues, 2014-2018 (GBP Million)
  • Table 21.10 ImmunoPrecise Antibodies: Annual Revenues, 2016-2021 (USD Million)
  • Table 21.11 Viva Biotech: Annual Revenues, 2016-H1 2021 (RMB Million)
  • Table 21.12 WuXi Biologics: Annual Revenues, 2015-H1 2021 (RMB Billion)
  • Table 21.13 Antibody Discovery Platform Providers: Distribution by Year of Establishment
  • Table 21.14 Antibody Discovery Platform Providers: Distribution by Company Size
  • Table 21.15 Antibody Discovery Platform Providers: Distribution by Location of Headquarters
  • Table 21.16 Antibody Discovery Platform Providers: Distribution by Type of Antibody Discovered
  • Table 21.17 Antibody Discovery Platforms: Distribution by Type of Antibody Discovery Method
  • Table 21.18 Antibody Discovery Platforms: Distribution by Animal Model Used
  • Table 21.19 Antibody Discovery Platforms: Distribution by Patent Availability
  • Table 21.20 ImmunoPrecise Antibodies: Annual Revenues, 2016-2021 (USD Million)
  • Table 21.21 Ligand Pharmaceuticals: Annual Revenues, 2014-9M 2021 (USD Million)
  • Table 21.22 MorphoSys: Annual Revenues, 2014-9M 2021 (USD Million)
  • Table 21.23 Partnerships and Collaborations: Cumulative Trend by Year, 2015-2021
  • Table 21.24 Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 21.25 Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2015-2020
  • Table 21.26 Partnerships and Collaborations: Distribution by Type of Company (Service / Platform Providers)
  • Table 21.27 Partnerships and Collaborations: Distribution by Type of Antibody Discovered
  • Table 21.28 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
  • Table 21.29 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
  • Table 21.30 Most Active Players: Distribution by Number of Partnerships
  • Table 21.31 Most Popular Technologies: Distribution by Number of Partnerships
  • Table 21.32 Partnerships and Collaborations: Regional Distribution
  • Table 21.33 Funding and Investment Analysis: Distribution by Type of Funding and Year of Establishment
  • Table 21.34 Funding and Investment Analysis: Cumulative Year-wise Distribution of Funding Instances, 2016-2021
  • Table 21.35 Funding and Investment Analysis: Year-wise Distribution of Funding Instances by Type of Company, (2016-2021)
  • Table 21.36 Funding and Investment Analysis: Distribution by Cumulative Amount Invested, 2016-2021 (USD Million)
  • Table 21.37 Funding and Investment Analysis: Year-wise Distribution of Funding Instances by Amount Invested, 2016-2021 (USD Million)
  • Table 21.38 Funding and Investment Analysis: Year-wise Distribution of the Amount Raised by Type of Company, 2016-2021 (USD Million)
  • Table 21.39 Funding and Investment Analysis: Distribution of Instances by Type of Funding,
  • Table 21.40 Funding and Investment Analysis: Distribution of Type of Funding and Amount Invested, (USD Million)
  • Table 21.41 Most Active Player: Distribution by Number of Funding Instances
  • Table 21.42 Most Active Player: Distribution by Total Amount Invested (USD Million)
  • Table 21.43 Most Active Investors: Distribution by Number of Funding Instances
  • Table 21.44 Funding and Investment Analysis: Distribution by Geography
  • Table 21.45 Funding and Investment Analysis: Regional Distribution of Funding Instances
  • Table 21.46 Global Antibody Discovery Services Market, 2021-2035 (USD Billion): Base, Conservative and Optimistic Scenarios
  • Table 21.47 Global Antibody Discovery Services Market: Distribution by Steps Involved in Antibody Discovery Process, 2021-2035: Base, Conservative and Optimistic Scenarios
  • Table 21.48 Antibody Discovery Services Market for Antigen Designing, 2021-2035
  • Table 21.49 Antibody Discovery Services Market for Hit Generation, 2021-2035
  • Table 21.50 Antibody Discovery Services Market for Lead Selection, 2021-2035
  • Table 21.51 Antibody Discovery Services Market for Lead Optimization, 2021-2035
  • Table 21.52 Antibody Discovery Services Market for Lead Characterization, 2021-2035
  • Table 21.53 Global Antibody Discovery Services Market: Distribution by Antibody Discovery Method, 2021-2035: Base, Conservative and Optimistic Scenarios
  • Table 21.54 Antibody Discovery Services Market for Phage Display, 2021-2035
  • Table 21.55 Antibody Discovery Services Market for Yeast Display, 2021-2035
  • Table 21.56 Antibody Discovery Services Market for Hybridoma Method, 2021-2035
  • Table 21.57 Antibody Discovery Services Market for Transgenic Animal Based Method, 2021-2035
  • Table 21.58 Antibody Discovery Services Market for Single Cell Based Method, 2021-2035
  • Table 21.59 Antibody Discovery Services Market for Other Methods, 2021-2035
  • Table 21.60 Global Antibody Discovery Services Market: Distribution by Nature of Antibody Generated, 2021-2035: Base, Conservative and Optimistic Scenarios
  • Table 21.61 Antibody Discovery Services Market for Humanized Antibodies, 2021-2035
  • Table 21.62 Antibody Discovery Services Market for Human Antibodies, 2021-2035
  • Table 21.63 Antibody Discovery Services Market for Chimeric Antibodies, 2021-2035
  • Table 21.64 Antibody Discovery Services Market for Murine Antibodies, 2021-2035
  • Table 21.65 Global Antibody Discovery Services Market: Distribution by Region, 2021-2035: Base, Conservative and Optimistic Scenarios
  • Table 21.66 Antibody Discovery Services Market in North America, 2021-2035
  • Table 21.67 Antibody Discovery Services Market in Europe, 2021-2035
  • Table 21.68 Antibody Discovery Services Market in Asia-Pacific and Rest of the World, 2021-2035
  • Table 21.69 Global Antibody Discovery Platforms Market, 2021-2035 (USD Million): Base, Conservative and Optimistic Scenarios
  • Table 21.70 Global Antibody Discovery Platforms Market: Distribution by Region, 2021-2035 (USD Million): Base, Conservative and Optimistic Scenarios
  • Table 21.71 Antibody Discovery Platforms Market in North America, 2021-2035
  • Table 21.72 Antibody Discovery Platforms Market in Europe, 2021-2035
  • Table 21.73 Antibody Discovery Platforms Market in Asia-Pacific, 2021-2035
  • Table 21.74 Humira®: Annual Sales, 2016-9M 2021 (USD Billion)
  • Table 21.75 Keytruda®: Annual Sales, 2016-9M 2021 (USD Billion)
  • Table 21.76 Stelara®: Annual Sales, 2016-9M 2021 (USD Billion)
  • Table 21.77 Opdivo®: Annual Sales, 2016-9M 2021 (USD Billion)
  • Table 21.78 Avastin®: Annual Sales, 2016-9M 2021 (CHF Million)
  • Table 21.79 Number of Licensing Deals, 2015- 2021

List Of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  • 1. 2BScientific
  • 2. 3D Medicines
  • 3. 3E Bioventures Capital
  • 4. 3SBio
  • 5. A*STAR's Genome Institute of Singapore
  • 6. AAT Bioquest
  • 7. Ab Initio Biotherapeutics
  • 8. Ab Studio
  • 9. ABBA Therapeutics
  • 10. AbBioSci
  • 11. Abbiotec
  • 12. AbbVie
  • 13. Abcam
  • 14. AbCellera
  • 15. Abcentra
  • 16. Abcepta
  • 17. AbCheck
  • 18. ABclonal
  • 19. Abcore
  • 20. ABDYS
  • 21. Abeome
  • 22. Abexxa Biologics
  • 23. ABGENEX
  • 24. AbGenics Life Sciences
  • 25. Abilita Bio
  • 26. ABL Bio
  • 27. Ablexis
  • 28. Abnova
  • 29. Abpro
  • 30. AbSano
  • 31. Absea
  • 32. Absolute Antibody
  • 33. Abveris
  • 34. AbVision
  • 35. Abwiz Bio
  • 36. Abzena
  • 37. Abzyme Therapeutics
  • 38. AC Immune
  • 39. Accel
  • 40. Acceleron Pharma
  • 41. Accurus Biosciences
  • 42. Achaogen
  • 43. ACYTE Biotech
  • 44. Adagene
  • 45. Adaptate Biotherapeutics
  • 46. Adimab
  • 47. Adipogen Life Sciences
  • 48. Aduro Biotech
  • 49. Advantech
  • 50. Advantech Capital
  • 51. AffinityImmuno
  • 52. Affitech
  • 53. Agency for Science, Technology and Research
  • 54. Agenus
  • 55. Agro-Bio
  • 56. AIMM Therapeutics
  • 57. Aimmune Therapeutics
  • 58. Aisling Capital
  • 59. Akeagen
  • 60. Akeso Biopharma
  • 61. Aldevron
  • 62. Alector
  • 63. Alligator Bioscience
  • 64. Allogene Therapeutics
  • 65. Alloy Therapeutics
  • 66. Ally Bridge
  • 67. AlpaLife
  • 68. Alta Partners
  • 69. Alvaxa Biosciences (Acquired by Sensei Biotherapeutics)
  • 70. ALX Oncology
  • 71. alytas therapeutics
  • 72. Alzheimer's Drug Discovery Foundation
  • 73. Amgen
  • 74. Amgen Ventures
  • 75. Ampersand Capital Partners
  • 76. AMSBIO
  • 77. AnaImmune
  • 78. Analytics Engine
  • 79. AnaptysBio
  • 80. Andera Partners
  • 81. Angel BioScience
  • 82. Antagene
  • 83. Antibody Design Labs
  • 84. Antibody Solutions
  • 85. Antiverse
  • 86. AP Biosciences
  • 87. Apexigen
  • 88. APITBIO
  • 89. Applied Biological Materials(abm)
  • 90. AprilBio
  • 91. Aptevo Therapeutics
  • 92. Aquila BioMedical
  • 93. Aquila Capital
  • 94. Aquilo Capital Management
  • 95. Aragen Bioscience
  • 96. ARCH Venture Partners
  • 97. Arcus Biosciences
  • 98. argenx
  • 99. Aridis Pharmaceuticals
  • 100. Aro Biotherapeutics
  • 101. Aronora
  • 102. Arsanis
  • 103. ArtiaBio
  • 104. Artizan Biosciences
  • 105. ARVYS Proteins
  • 106. Assistant Secretary for Preparedness and Response
  • 107. Astellas Pharma
  • 108. AstraZeneca
  • 109. aTen Therapeutics
  • 110. Atreca
  • 111. ATUM
  • 112. Autolus Therapeutics
  • 113. AvantGen
  • 114. AVIC Capital
  • 115. Aviva Systems Biology
  • 116. AxioMx
  • 117. Ballast Point Ventures
  • 118. Bayer
  • 119. BBI Group
  • 120. BeiGene
  • 121. Beijing Shijilongxin Investment
  • 122. BenchSci
  • 123. Berkeley Lights
  • 124. Betta Pharmaceuticals
  • 125. BRL
  • 126. Bharat Innovation Fund
  • 127. Bhat Bio-tech
  • 128. Bill & Melinda Gates Foundation
  • 129. Bio- Rad Laboratories
  • 130. BioAtla
  • 131. BioConnect
  • 132. Biocure Technology
  • 133. Biocytogen
  • 134. BioDiscovery
  • 135. BioDuro
  • 136. Biogen
  • 137. Biointron
  • 138. BioInvent
  • 139. BiologicsCorp(BIC)
  • 140. Biomatics Capital
  • 141. Biomolecular Discovery Services
  • 142. BioNTech
  • 143. Bio-Rad Laboratories
  • 144. BioSavita
  • 145. Biosion
  • 146. Biotechnology Value Fund
  • 147. Biotecnol
  • 148. BIOTEM
  • 149. Biotheus
  • 150. Bioz
  • 151. Birchmere Labs
  • 152. Bird Rock Bio
  • 153. Blue Sky BioServices
  • 154. bluebird bio
  • 155. Boehringer Ingelheim
  • 156. Boster Bio
  • 157. Boston Children's Hospital
  • 158. Boxer Capital
  • 159. Brain Canada
  • 160. Bristol-Myers Squibb
  • 161. Broteio Pharma
  • 162. Burrage Capital
  • 163. CALIXAR
  • 164. CANbridge
  • 165. Cancer Prevention and Research Institute of Texas
  • 166. Capra Science
  • 167. Capralogics
  • 168. Carterra
  • 169. Catalent Biologics
  • 170. CBC Group
  • 171. CCB Capital
  • 172. CDH Investments
  • 173. CDI Laboratories
  • 174. Celexion
  • 175. Celgene
  • 176. Cell Signaling Technology
  • 177. Cellaria
  • 178. Celsius Therapeutics
  • 179. Centers for Disease Control and Prevention (CDC)
  • 180. Charles River Laboratories
  • 181. ChemBio Discovery Solutions
  • 182. Chemical Abstracts Service (CAS)
  • 183. ChemPartner
  • 184. Chia Tai Tianqing Pharmaceutical
  • 185. China Life Investment Holding
  • 186. China Life Private Equity Investment
  • 187. ChinaEquity Group (CEG)
  • 188. Chiome Bioscience
  • 189. Chugai Pharmabody Research
  • 190. Chugai Pharmaceutical
  • 191. Cilag
  • 192. Citryll
  • 193. City of Hope
  • 194. Columbia University Irving Medical Center
  • 195. Compass Therapeutics
  • 196. Cormorant Asset Management
  • 197. Corvidia Therapeutics
  • 198. Cosmo Bio
  • 199. Cowen Healthcare Investments
  • 200. Cowin Venture Capital
  • 201. CR-CP Life Science Fund
  • 202. Creative Biolabs
  • 203. Creative Biostructure
  • 204. Creative Diagnostics
  • 205. Crescendo Biologics
  • 206. Crystal Bioscience
  • 207. CSL Behring
  • 208. CStone Pharmaceuticals
  • 209. CureVac
  • 210. CUSABIO
  • 211. Cyclogenix
  • 212. Cygnus Technologies
  • 213. DAFNA Capital Management
  • 214. Daiichi Sankyo
  • 215. Dako
  • 216. Dana-Farber Cancer Institute
  • 217. DaTaMabs
  • 218. DBA ITALIA
  • 219. DCVC (Data Collective)
  • 220. Decheng Capital
  • 221. Defense Advanced Research Projects Agency (DARPA)
  • 222. Delian Capital
  • 223. Denali Therapeutics
  • 224. Detaibio Tech
  • 225. Diagnostic BioSystems
  • 226. Dianomi Therapeutics
  • 227. Diatheva
  • 228. Digital Proteomics
  • 229. Distributed Bio
  • 230. DJS Antibodies
  • 231. Dotmatics
  • 232. Dualogics
  • 233. Early Drug Development Group (E2DG)
  • 234. EcoR1 Capital
  • 235. Efung Capital
  • 236. Eight Roads
  • 237. Eisai
  • 238. Elabscience
  • 239. Eli Lilly and Company
  • 240. Elpis Biopharmaceuticals
  • 241. Emergent BioSolutions
  • 242. E-nnovation Life Sciences
  • 243. Enterprise Singapore
  • 244. Enthera
  • 245. Entos Pharmaceuticals
  • 246. Envigo
  • 247. EpimAb Biotherapeutics
  • 248. Epiphron Capital Group
  • 249. EUPROTEIN
  • 250. Eureka Therapeutics
  • 251. European Investment Bank
  • 252. European Molecular Biology Laboratory (EMBL)
  • 253. Eurostars
  • 254. Evotec
  • 255. Exelixis
  • 256. Exiris
  • 257. exonbio
  • 258. FairJourney Biologics
  • 259. Faron Pharmaceuticals
  • 260. FCMI Parent
  • 261. Ferring Pharmaceuticals
  • 262. Five Prime Therapeutics
  • 263. Flagship Pioneering
  • 264. Flanders Innovation and Entrepreneurship
  • 265. Floodgate
  • 266. ForteBio
  • 267. Fortune Capital Services
  • 268. Forty Seven
  • 269. F-Prime Capital
  • 270. Fred Hutchinson Cancer Research Center
  • 271. FREJOY Investment Management
  • 272. Fusion Antibodies
  • 273. Fusion Pharmaceuticals
  • 274. G&P Biosciences
  • 275. G.N. Tech Venture
  • 276. Genagon Therapeutics
  • 277. Gene Techno Science
  • 278. GeneBeyond
  • 279. Genedata Biologics
  • 280. GeneFrontier
  • 281. Geneious Biologics
  • 282. General Atlantic
  • 283. GENEWIZ
  • 284. Genmab
  • 285. Genor Biopharma
  • 286. GenoSafe
  • 287. Genosco
  • 288. GenScript
  • 289. GenWay Biotech
  • 290. GHO Capital
  • 291. GIC
  • 292. GigaGen
  • 293. Gilead Sciences
  • 294. GSK
  • 295. Glenmark Pharmaceuticals
  • 296. Glythera
  • 297. Gopher Asset Management
  • 298. GP Healthcare Capital
  • 299. Green Mountain Antibodies
  • 300. Grenoble Alpes University Hospital
  • 301. Grifols
  • 302. Gustave Roussy
  • 303. GV20 Oncotherapy
  • 304. H3 Biomedicine
  • 305. Harbour BioMed
  • 306. Harpoon Therapeutics
  • 307. HD Biosciences
  • 308. Helix BioPharma
  • 309. Henlix Biotech
  • 310. Heptares Therapeutics
  • 311. Hercules Capital
  • 312. Heritas Capital Management
  • 313. HiFiBiO Therapeutics
  • 314. Hillhouse Capital
  • 315. HJB
  • 316. Hony Capital
  • 317. HOPU Investments
  • 318. Horizon Discovery
  • 319. Huaxing Growth Capital
  • 320. Hummingbird Bioscience
  • 321. i2 Pharmaceuticals
  • 322. Ibex Biosciences
  • 323. Icosagen
  • 324. IDG Capital
  • 325. IFB Hamburg
  • 326. IGEM Therapeutics
  • 327. I-Mab Biopharma
  • 328. iMetabolic Biopharma
  • 329. Immatics Biotechnologies
  • 330. Immune Biosolutions
  • 331. Immune Pharmaceuticals
  • 332. ImmunoChina Pharmaceuticals
  • 333. ImmunoGenes
  • 334. Immunome
  • 335. Immunomic Therapeutics
  • 336. ImmunoPrecise Antibodies
  • 337. ImmunoQure
  • 338. In-Cell-Art
  • 339. Incyte
  • 340. Indivumed
  • 341. Inhibrx
  • 342. Innate Pharma
  • 343. Innogene Kalbiotech
  • 344. Innovagen
  • 345. Innovate UK
  • 346. Innovative Targeting Solutions
  • 347. Innovent Biologics
  • 348. Inotiv
  • 349. Institut National de la Santé et de la Recherche Médicale (INSERM)
  • 350. Institute for Research in Biomedicine
  • 351. Intarcia Therapeutics
  • 352. Integral Molecular
  • 353. IntelliCyt
  • 354. International Livestock Research Institute (ILRI)
  • 355. Invenra
  • 356. Invest Northern Ireland
  • 357. Invetx
  • 358. IONTAS
  • 359. IP
  • 360. IRBM
  • 361. Isogenica
  • 362. Italian National Institute of Health
  • 363. ITBMed
  • 364. iTeos Therapeutics
  • 365. Janssen Biotech
  • 366. Janssen Pharmaceutical
  • 367. JDRF T1D Fund
  • 368. Jiangsu Hengrui Medicine
  • 369. Johnson & Johnson Innovation
  • 370. Jounce Therapeutics
  • 371. Juno Therapeutics
  • 372. Just Biotherapeutics (Acquired by Evotec)
  • 373. JW Bioscience
  • 374. Kadmon
  • 375. Kairos Therapeutics
  • 376. Kaken Pharmaceutical
  • 377. Karolinska Institutet
  • 378. Kemp Proteins (formerly known as Kempbio)
  • 379. Keystone Capital Partners
  • 380. Kite Pharma
  • 381. KMD
  • 382. Kodiak Sciences
  • 383. Kymab
  • 384. LabCorp
  • 385. Labtoo
  • 386. LakePharma
  • 387. LAMPIRE Biological Laboratories
  • 388. Lanier Biotherapeutics
  • 389. Lava Therapeutics
  • 390. Leadgene Biomedical
  • 391. Leading Biology
  • 392. Legend Capital
  • 393. Legend Star
  • 394. Leidos Biomedical Research
  • 395. LEO Pharma
  • 396. LG Chem
  • 397. Life Science Partners
  • 398. LifeArc
  • 399. LifeTein
  • 400. Ligand Pharmaceuticals
  • 401. Light Chain Bioscience
  • 402. Lilly Ventures
  • 403. Lineage Biosciences (Acquired by AbCellera)
  • 404. Linear Venture
  • 405. Lipum
  • 406. Lonza
  • 407. Lundbeck
  • 408. Luye Pharma
  • 409. LYFE Capital
  • 410. MAB Discovery
  • 411. MabGenesis
  • 412. Mablytics
  • 413. Mabpharm
  • 414. MAbSilico
  • 415. MabSpace Biosciences
  • 416. Mabtech
  • 417. MabVax Therapeutics
  • 418. MacroGenics
  • 419. Magenta Therapeutics
  • 420. Maine Biotechnology Services
  • 421. Malin
  • 422. Maravai LifeSciences
  • 423. Massachusetts General Hospital
  • 424. MassBiologics
  • 425. Maverick Therapeutics
  • 426. MD Anderson Cancer Center
  • 427. MedAbome
  • 428. Medicilon
  • 429. MedImmune
  • 430. Medix Biochemica
  • 431. MEMO Therapeutics
  • 432. Memorial Sloan Kettering Cancer Center
  • 433. Merck
  • 434. Merus
  • 435. MI-mAbs
  • 436. Mirae Asset Financial
  • 437. Mitsubishi Tanabe Pharma
  • 438. Mitsubishi UFJ Capital
  • 439. ModiQuest Research
  • 440. Molcure
  • 441. Molecular Devices
  • 442. Molecular Templates
  • 443. MolMed
  • 444. Moradec
  • 445. MorphoSys
  • 446. Mount Sinai Health System
  • 447. MPM Capital
  • 448. MRL Ventures Fund
  • 449. MSM Protein Technologies
  • 450. Mycenax Biotech
  • 451. Myrio Therapeutics (Myrio)
  • 452. NanoString Technologies
  • 453. Nara Medical University
  • 454. National Cancer Institute
  • 455. National Center for Research and Development
  • 456. National Centre for Biomolecular Research
  • 457. National Heart, Lung and Blood Institute
  • 458. National Institute of Allergy and Infectious Diseases
  • 459. National Institute of General Medical Sciences
  • 460. National Institutes of Health
  • 461. NB Health Laboratory
  • 462. NBE-Therapeutics
  • 463. NeoBiotechnologies
  • 464. NeoClone
  • 465. Neon Therapeutics
  • 466. neoX Biotech
  • 467. Nest.Bio Ventures
  • 468. Neurimmune
  • 469. New World TMT
  • 470. Nidus BioSciences
  • 471. NJCTTQ
  • 472. Nkarta Therapeutics
  • 473. North Coast Biologics
  • 474. NovaRock Biotherapeutics
  • 475. Novartis
  • 476. Novo Nordisk
  • 477. Numab Therapeutics
  • 478. NYU Langone Health
  • 479. Oak Biosciences
  • 480. Oblique Therapeutics
  • 481. Oceanpine Capital
  • 482. Olympic Protein Technologies
  • 483. Oncothyreon
  • 484. Ono Pharmaceutical
  • 485. Open Monoclonal Technology
  • 486. OrbiMed Advisors
  • 487. OREGA Biotech
  • 488. ORI Healthcare Fund
  • 489. OriGene Technologies
  • 490. OriMAbs
  • 491. OSE Immunotherapeutics
  • 492. Ossianix
  • 493. Oxford Sciences Innovation
  • 494. Paladin Capital
  • 495. Pandion Therapeutics
  • 496. Panoply Bio
  • 497. Pascal Biosciences
  • 498. Pediatric Brain Tumor Consortium
  • 499. Penn Medicine
  • 500. Pennsylvania Industrial Development Authority
  • 501. Perseus Proteomics
  • 502. Pfizer
  • 503. pH Pharma
  • 504. Phanes Therapeutics
  • 505. PharmAbcine
  • 506. PharmaLegacy
  • 507. Pierre Fabre
  • 508. Polaris Partners
  • 509. Potenza Therapeutics
  • 510. PPF
  • 511. Precision Antibody
  • 512. ProMab Biotechnologies
  • 513. Protein Alternatives (PROALT)
  • 514. ProteoGenix
  • 515. ProtTech
  • 516. Proxima Ventures
  • 517. Purdue Pharma
  • 518. Pure Biologics
  • 519. PX'Therapeutics
  • 520. Qianhai Qinzhi Capital
  • 521. Qiming Venture Partners
  • 522. QIMR Berghofer Medical Research Institute
  • 523. QoolAbs
  • 524. Quan Funds
  • 525. Quebec Consortium for Drug Discovery (CQDM)
  • 526. Queen's University
  • 527. Rapid Novor
  • 528. RayBiotech
  • 529. RD-Biotech
  • 530. Redalpine Venture Partners
  • 531. Redmile
  • 532. Regeneron Pharmaceuticals
  • 533. Regione Lazio
  • 534. Resonant Therapeutics
  • 535. Retrogenix
  • 536. RevMab Biosciences
  • 537. Revolve Biotechnologies
  • 538. Rezolute
  • 539. Rhenman & Partners Asset Management
  • 540. Roche
  • 541. Rockland Immunochemicals
  • 542. RubrYc Therapeutics
  • 543. Rx Biosciences
  • 544. SAB Biotherapeutics
  • 545. Sahlgrenska University Hospital
  • 546. Samsara BioCapital
  • 547. Samsara Networks
  • 548. San Diego Biomedical Research Institute
  • 549. Sanofi
  • 550. Sanyou Biopharmaceuticals
  • 551. SARomics Biostructures
  • 552. Sartorius
  • 553. SBH Sciences
  • 554. Schroder Adveq
  • 555. Science Exchange
  • 556. Scotia Biologics
  • 557. Sea Lane Biotechnologies
  • 558. Seeds Capital
  • 559. Selecxine
  • 560. Sensei Biotherapeutics
  • 561. Sequoia Capital China
  • 562. Serum Institute of India
  • 563. Sevion Therapeutics
  • 564. Shandong Boan Biotechnology
  • 565. Shanghai Junshi Biosciences
  • 566. Shenyang Sunshine Pharmaceuticals
  • 567. Shenzhen GTJA Investment Group
  • 568. Shenzhen Hepalink Pharmaceutical
  • 569. Shenzhen Innovation Capital Investment
  • 570. Shilps Sciences
  • 571. Shire
  • 572. Sichenzia Ross Ference
  • 573. Sichuan Kelun-Biotech Biopharmaceutical
  • 574. Siegfried Holding
  • 575. Silverton Partners
  • 576. Simcere Pharmaceutical
  • 577. Simon Fraser University
  • 578. Single Cell Technology
  • 579. Sino Biological
  • 580. Sinobioway
  • 581. Six.02 Bioservices
  • 582. SK Holdings
  • 583. Sofinnova Partners
  • 584. Sorrento Therapeutics
  • 585. SOTIO
  • 586. South Dakota Equity Partners
  • 587. SouthernBiotech
  • 588. Specifica
  • 589. Sphere Fluidics
  • 590. Standford University
  • 591. State Development & Investment
  • 592. State of Wisconsin Investment Board (SWIB)
  • 593. Straterx
  • 594. Summit Partners
  • 595. Surface Oncology
  • 596. Surveyor Capital
  • 597. Sutro Biopharma
  • 598. Suzhou Bright Scistar Biotechnology (BSBIO)
  • 599. Suzhou Oriza Holdings
  • 600. Syd Labs
  • 601. Symphogen
  • 602. Synbio Technologies
  • 603. Syngene
  • 604. Synthelis
  • 605. TA Associates
  • 606. Takeda
  • 607. Talem Therapeutics
  • 608. Tanabe Research Laboratories
  • 609. Tasgen Bio-Tech
  • 610. Tasly Biopharmaceuticals
  • 611. TC BioPharm
  • 612. Technical University of Denmark
  • 613. Telix Pharmaceuticals
  • 614. Temasek Holdings
  • 615. TeneoBio
  • 616. TESARO
  • 617. TetraGenetics
  • 618. Teva Pharmaceutical Industries
  • 619. TG Therapeutics
  • 620. The Antibody Company
  • 621. The University of Texas MD Anderson Cancer Center
  • 622. The University of Tokyo
  • 623. The Wistar Institute
  • 624. Theraclone Sciences
  • 625. Theranyx
  • 626. Thermo Fisher Scientific
  • 627. Thiel Capital
  • 628. Third Point Ventures
  • 629. Third Venture Biopharma
  • 630. ThromboGenics
  • 631. Tizona Therapeutics
  • 632. Tmunity Therapeutics
  • 633. Torch Biosciences
  • 634. TRACON Pharmaceuticals
  • 635. Transcenta Holding
  • 636. Transgene
  • 637. TRIANNI
  • 638. Tri-Institutional Therapeutics Discovery Institute
  • 639. Tsinghua University
  • 640. Twist Biopharma
  • 641. Twist Bioscience
  • 642. UK Innovation & Science Seed Fund
  • 643. University College London
  • 644. University of Navarra
  • 645. University of Oxford
  • 646. University of Southampton
  • 647. University of Surrey
  • 648. University of Technology Sydney
  • 649. University of Texas
  • 650. U-Protein Express
  • 651. US Department of Defense
  • 652. Vaccinex
  • 653. Vall d'Hebron Institute of Oncology
  • 654. Valneva
  • 655. Velabs Therapeutics
  • 656. venBio
  • 657. VERAXA Biotech
  • 658. Vertex Holdings
  • 659. VI Ventures
  • 660. Vinnova
  • 661. Vir Biotechnology
  • 662. Visterra
  • 663. Vital Venture Capital
  • 664. Viva Biotech
  • 665. Voyager Therapeutics
  • 666. Washington University School of Medicine
  • 667. Watson Investments
  • 668. Wellington Management
  • 669. Wisconsin Alumni Research Foundation
  • 670. Woodford Investment Management
  • 671. Woodford Patient Capital Trust
  • 672. WuXi AppTec
  • 673. Wuxi Biologics
  • 674. XBiotech
  • 675. xCella Biosciences
  • 676. X-Chem
  • 677. Xencor
  • 678. XOMA
  • 679. Y- Biologics
  • 680. Yale Cancer Center
  • 681. Yinuoke
  • 682. YUMAB
  • 683. Yurogen Biosystems
  • 684. Zai Lab
  • 685. Zebra Biologics
  • 686. Zhejiang Teruisi Pharmaceutical
  • 687. Zheshang Venture Capital
  • 688. ZoonBio Biotechnology
  • 689. Zumutor Biologics
  • 690. Zurich Cantonal Bank
  • 691. Zydus Cadila
  • 692. Zymeworks